Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (157)	12/5/1998 12:09:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 666

V1: >> The Euro royalty is double digit << Didn't know that. Was assuming such, but didn't know that there was any basis for my assump. Thanks. >> I believe the successful biotechs are going to fill some of the funding gap for the smaller companies. << Given my investing life down in the third-tier trenches, can't happen quickly enough. Cheers! Rick

To: Vector1 who wrote (157)	12/8/1998 8:53:00 PM
From: Bob L	Read Replies (1) \| Respond to of 666

Vector1, what is your view of the remarks about FDA filing in the latest press release? On the one hand they announce fast-track status, but then say "With our completed pivotal trial and additional supportive clinical data, we are working closely with the FDA towards submitting the first portions of our Biologics License Application for our I-131 Anti-B1 Antibody to the FDA over the next few months." This doesn't sound quite the same as submitting by the end of this year, which is what they have said before. It seems to give some support to those who say the phase III didn't provide enough good data. Overall, the news of late has been great. But I wonder if the timetable has actually slid a bit, despite the fast track status.